US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mira Pharma

1.66

+0.14009.21%

Post-market: 1.66-0.0003-0.02%17:21 EDT

Volume:560.18K

Turnover:908.41K

Market Cap:31.66M

PE:-3.58

High:1.68

Open:1.55

Low:1.55

Close:1.52

52wk High:2.56

52wk Low:0.7300

Shares:19.07M

Float Shares:14.81M

Volume Ratio:3.04

T/O Rate:3.78%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4640

EPS(LYR):-0.5085

ROE:-556.87%

ROA:-253.31%

PB:55.55

PE(LYR):-3.26

Loading ...

Overview Company News Filings

BRIEF-Mira Pharmaceuticals says Mira-55 Shows Morphine-Comparable Pain Relief Without Opioid Risks

MIRA Pharmaceuticals Advances with Regulatory Green Light for Mira-55, Clearing Path for Clinical Development in Pain Management

BRIEF-Mira Pharmaceuticals Announces New Study Results For SKNY-1 - SEC Filing

Mira Pharmaceuticals Unveils Promising Results for SKNY-1, Showing 30% Weight Loss and Reduced Cravings in Obesity Study

Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1

MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025

Mira Pharmaceuticals Advances Ketamir-2 Development with SEC Regulatory Filings for SKNY Pharmaceuticals Acquisition

Mira Pharmaceuticals Inc. Announces Date for Virtual Special Meeting

Mira Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CFO Alan Weichselbaum

Mira Pharmaceuticals Nears Finalization of SKNY Pharmaceuticals Acquisition with Regulatory Filings Imminent

BRIEF-Mira Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals - SEC Filing

BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC Filing

MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Enterprise Value to Over $60 Million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MIRA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MIRA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","market":"US","secType":"STK","nameCN":"Mira Pharma","latestPrice":1.66,"timestamp":1757620800000,"preClose":1.52,"halted":0,"volume":560181,"hourTrading":{"tag":"盘后","latestPrice":1.6597,"preClose":1.66,"latestTime":"17:21 EDT","volume":13840,"amount":22808.713056,"timestamp":1757625704997},"delay":0,"floatShares":14806099,"shares":19069315,"eps":-0.464032,"marketStatus":"Post-Mkt","change":0.14,"latestTime":"09-11 17:23:46 EDT","open":1.55,"high":1.68,"low":1.55,"amount":908405.1386499,"amplitude":0.085526,"askPrice":1.66,"askSize":415,"bidPrice":1.62,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-0.464032,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1757635200000},"marketStatusCode":4,"adr":0,"listingDate":1691035200000,"exchange":"NASDAQ","adjPreClose":1.52,"preHourTrading":{"tag":"盘前","latestPrice":1.55,"preClose":1.52,"latestTime":"09:29 EDT","volume":32356,"amount":52944.9575848,"timestamp":1757597344999},"postHourTrading":{"tag":"盘后","latestPrice":1.6597,"preClose":1.66,"latestTime":"17:21 EDT","volume":13840,"amount":22808.713056,"timestamp":1757625704997},"volumeRatio":3.044346},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MIRA\",,,,,undefined,":{"symbol":"MIRA","floatShares":14806099,"roa":"-253.31%","roe":"-556.87%","lyrEps":-0.508455,"volumeRatio":3.044346,"shares":19069315,"dividePrice":0,"high":1.68,"amplitude":0.085526,"preClose":1.52,"low":1.55,"week52Low":0.73,"pbRate":"55.55","week52High":2.56,"institutionHeld":0,"latestPrice":1.66,"committee":0.656315,"eps":-0.464032,"divideRate":0,"volume":560181,"delay":0,"ttmEps":-0.464032,"open":1.55,"prevYearClose":1.14,"prevWeekClose":1.4,"prevMonthClose":1.37,"prevQuarterClose":1.21,"fiveDayClose":1.38,"twentyDayClose":1.49,"sixtyDayClose":1.25},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MIRA\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-08-14","symbol":"MIRA","fiscalQuarterEnding":"2025/06","expectedEps":-0.11,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1755144000000,"reportTimeType":"post","actualEps":-0.09}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MIRA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MIRA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1755576000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MIRA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MIRA","date":"2025-09-10","current":-3.462659,"percent":0.209581,"low":-15.501022,"twenty":-3.506863,"median":-2.132112,"eighty":-1.474654,"high":-0.648567,"avg":-3.277723,"sd":3.247115,"marketCap":26887734},"quantilePoints":[{"date":"2023-08-04","current":-15.501022,"twenty":-15.501022,"median":-15.501022,"eighty":-15.501022,"marketCap":109409161},{"date":"2023-08-11","current":-14.407729,"twenty":-14.826558,"median":-14.407729,"eighty":-13.088417,"marketCap":101692488},{"date":"2023-08-18","current":-13.611953,"twenty":-14.407729,"median":-13.779485,"eighty":-13.130299,"marketCap":96075752},{"date":"2023-08-25","current":-13.193124,"twenty":-14.407729,"median":-13.42348,"eighty":-13.109358,"marketCap":93119575},{"date":"2023-09-01","current":-13.137838,"twenty":-14.303022,"median":-13.371126,"eighty":-13.130299,"marketCap":92729360},{"date":"2023-09-07","current":-12.209294,"twenty":-13.9889,"median":-13.365891,"eighty":-13.071664,"marketCap":86175515},{"date":"2023-09-15","current":-7.434221,"twenty":-13.678966,"median":-13.193124,"eighty":-12.686741,"marketCap":52472141},{"date":"2023-09-22","current":-11.507289,"twenty":-13.511434,"median":-13.119829,"eighty":-11.928492,"marketCap":66366173},{"date":"2023-09-29","current":-12.263336,"twenty":-13.419292,"median":-13.046534,"eighty":-11.42538,"marketCap":70726534},{"date":"2023-10-06","current":-12.045492,"twenty":-13.402539,"median":-12.816178,"eighty":-11.507289,"marketCap":69470159},{"date":"2023-10-13","current":-7.586097,"twenty":-13.383691,"median":-12.460173,"eighty":-11.225373,"marketCap":43751419},{"date":"2023-10-20","current":-8.457473,"twenty":-13.371126,"median":-12.263336,"eighty":-10.752267,"marketCap":48776920},{"date":"2023-10-27","current":-6.022746,"twenty":-13.371126,"median":-12.209294,"eighty":-9.627991,"marketCap":34735079},{"date":"2023-11-03","current":-3.818677,"twenty":-13.36275,"median":-12.045492,"eighty":-8.098671,"marketCap":22023518},{"date":"2023-11-10","current":-3.793048,"twenty":-13.343902,"median":-11.968606,"eighty":-7.418465,"marketCap":21875709},{"date":"2023-11-17","current":-6.622011,"twenty":-13.222442,"median":-11.712319,"eighty":-5.991992,"marketCap":49959391},{"date":"2023-11-24","current":-6.405718,"twenty":-13.159952,"median":-11.404903,"eighty":-6.252529,"marketCap":48327581},{"date":"2023-12-01","current":-6.955071,"twenty":-13.133315,"median":-11.148487,"eighty":-6.405718,"marketCap":52472141},{"date":"2023-12-08","current":-3.546106,"twenty":-13.117734,"median":-10.762135,"eighty":-5.961237,"marketCap":26753401},{"date":"2023-12-15","current":-2.977946,"twenty":-13.096793,"median":-9.110163,"eighty":-5.156496,"marketCap":22466945},{"date":"2023-12-22","current":-2.066929,"twenty":-13.063287,"median":-8.611245,"eighty":-3.869935,"marketCap":15593833},{"date":"2023-12-29","current":-2.155092,"twenty":-13.025592,"median":-8.1243,"eighty":-3.839181,"marketCap":16258973},{"date":"2024-01-05","current":-2.272643,"twenty":-12.962768,"median":-7.893642,"eighty":-3.762396,"marketCap":17145826},{"date":"2024-01-12","current":-1.929591,"twenty":-12.874813,"median":-7.640782,"eighty":-3.079823,"marketCap":14557693},{"date":"2024-01-19","current":-1.608482,"twenty":-12.807801,"median":-7.444864,"eighty":-2.883906,"marketCap":12135106},{"date":"2024-01-26","current":-2.292235,"twenty":-12.642964,"median":-7.355439,"eighty":-2.366683,"marketCap":17293635},{"date":"2024-02-02","current":-1.880808,"twenty":-12.498268,"median":-7.111805,"eighty":-2.256969,"marketCap":14189649},{"date":"2024-02-09","current":-1.950359,"twenty":-12.397348,"median":-6.788541,"eighty":-2.206031,"marketCap":14714371},{"date":"2024-02-16","current":-2.01795,"twenty":-12.300188,"median":-6.405718,"eighty":-2.186439,"marketCap":15224311},{"date":"2024-02-23","current":-2.076725,"twenty":-12.241719,"median":-6.022746,"eighty":-2.135501,"marketCap":15667738},{"date":"2024-03-01","current":-1.968971,"twenty":-12.205282,"median":-5.750179,"eighty":-2.104154,"marketCap":14854789},{"date":"2024-03-08","current":-1.86102,"twenty":-12.137755,"median":-4.971969,"eighty":-2.061052,"marketCap":14040362},{"date":"2024-03-15","current":-2.409785,"twenty":-12.045492,"median":-3.957585,"eighty":-2.070847,"marketCap":18180488},{"date":"2024-03-22","current":-2.46856,"twenty":-12.014738,"median":-3.869935,"eighty":-2.084562,"marketCap":18623915},{"date":"2024-03-28","current":-2.135501,"twenty":-11.968606,"median":-3.818677,"eighty":-2.096317,"marketCap":16111164},{"date":"2024-04-05","current":-1.258227,"twenty":-11.958355,"median":-3.592948,"eighty":-2.059093,"marketCap":15076502},{"date":"2024-04-12","current":-1.209008,"twenty":-11.917349,"median":-3.095496,"eighty":-2.037542,"marketCap":14486745},{"date":"2024-04-19","current":-1.033719,"twenty":-11.835337,"median":-3.026925,"eighty":-1.978767,"marketCap":12386381},{"date":"2024-04-26","current":-1.1102,"twenty":-11.507289,"median":-2.977946,"eighty":-1.941738,"marketCap":13302796},{"date":"2024-05-03","current":-0.996589,"twenty":-11.466334,"median":-2.723253,"eighty":-1.872971,"marketCap":11941476},{"date":"2024-05-10","current":-0.925167,"twenty":-11.297339,"median":-2.546927,"eighty":-1.840684,"marketCap":11085663},{"date":"2024-05-17","current":-0.812651,"twenty":-11.251002,"median":-2.419581,"eighty":-1.782849,"marketCap":10043611},{"date":"2024-05-24","current":-1.05244,"twenty":-11.138236,"median":-2.390193,"eighty":-1.612165,"marketCap":13007178},{"date":"2024-05-31","current":-0.956764,"twenty":-11.09723,"median":-2.331418,"eighty":-1.319904,"marketCap":11824708},{"date":"2024-06-07","current":-0.922081,"twenty":-10.81147,"median":-2.30203,"eighty":-1.233679,"marketCap":11396062},{"date":"2024-06-14","current":-0.849247,"twenty":-10.732533,"median":-2.292235,"eighty":-1.18937,"marketCap":10495906},{"date":"2024-06-21","current":-0.875439,"twenty":-10.189973,"median":-2.272643,"eighty":-1.090284,"marketCap":10819607},{"date":"2024-06-28","current":-0.77737,"twenty":-9.841423,"median":-2.272643,"eighty":-1.073193,"marketCap":9607575},{"date":"2024-07-05","current":-0.687674,"twenty":-9.256415,"median":-2.262847,"eighty":-1.05424,"marketCap":8499008},{"date":"2024-07-12","current":-0.717692,"twenty":-8.841445,"median":-2.213868,"eighty":-1.045463,"marketCap":8870009},{"date":"2024-07-15","current":-0.704656,"twenty":-8.774265,"median":-2.213868,"eighty":-1.033719,"marketCap":8708897},{"date":"2024-08-02","current":-2.906169,"twenty":-8.772416,"median":-2.213868,"eighty":-1.036655,"marketCap":35917550},{"date":"2024-08-09","current":-2.535423,"twenty":-8.703509,"median":-2.262847,"eighty":-1.048424,"marketCap":31335476},{"date":"2024-08-16","current":-2.173611,"twenty":-8.390838,"median":-2.272643,"eighty":-1.04904,"marketCap":27788063},{"date":"2024-08-23","current":-2.162049,"twenty":-8.098671,"median":-2.248016,"eighty":-1.051378,"marketCap":27640254},{"date":"2024-08-30","current":-2.162049,"twenty":-7.95515,"median":-2.242981,"eighty":-1.05289,"marketCap":27640254},{"date":"2024-09-06","current":-1.826758,"twenty":-7.791127,"median":-2.23142,"eighty":-1.05469,"marketCap":23353798},{"date":"2024-09-13","current":-1.549276,"twenty":-7.650578,"median":-2.222644,"eighty":-1.05842,"marketCap":19806385},{"date":"2024-09-20","current":-1.341164,"twenty":-7.640782,"median":-2.194276,"eighty":-1.060611,"marketCap":17145826},{"date":"2024-09-27","current":-1.237108,"twenty":-7.586097,"median":-2.16783,"eighty":-1.073193,"marketCap":15815546},{"date":"2024-10-04","current":-1.352726,"twenty":-7.444864,"median":-2.155092,"eighty":-1.083185,"marketCap":17293635},{"date":"2024-10-11","current":-1.24867,"twenty":-7.434221,"median":-2.147009,"eighty":-1.095016,"marketCap":15963355},{"date":"2024-10-18","current":-1.260232,"twenty":-7.355439,"median":-2.135501,"eighty":-1.1102,"marketCap":16111164},{"date":"2024-10-25","current":-1.437761,"twenty":-7.355439,"median":-2.125705,"eighty":-1.110817,"marketCap":18380747},{"date":"2024-10-31","current":-2.79918,"twenty":-7.270245,"median":-2.125705,"eighty":-1.18937,"marketCap":35785525},{"date":"2024-11-08","current":-2.150279,"twenty":-7.139233,"median":-2.135501,"eighty":-1.21299,"marketCap":27489790},{"date":"2024-11-15","current":-2.170683,"twenty":-7.064784,"median":-2.135501,"eighty":-1.218696,"marketCap":24399222},{"date":"2024-11-22","current":-1.856409,"twenty":-6.974663,"median":-2.135501,"eighty":-1.224412,"marketCap":20866673},{"date":"2024-11-29","current":-1.90061,"twenty":-6.755235,"median":-2.115909,"eighty":-1.229612,"marketCap":21363499},{"date":"2024-12-06","current":-1.753275,"twenty":-6.551481,"median":-2.101597,"eighty":-1.233136,"marketCap":19707413},{"date":"2024-12-13","current":-1.650142,"twenty":-6.445215,"median":-2.081117,"eighty":-1.235736,"marketCap":18548154},{"date":"2024-12-20","current":-1.473341,"twenty":-6.405718,"median":-2.071827,"eighty":-1.237108,"marketCap":16560852},{"date":"2024-12-27","current":-1.768009,"twenty":-6.252529,"median":-2.060335,"eighty":-1.241733,"marketCap":19873022},{"date":"2025-01-03","current":-1.694342,"twenty":-5.991992,"median":-2.057134,"eighty":-1.250581,"marketCap":19044979},{"date":"2025-01-10","current":-1.959543,"twenty":-5.868974,"median":-2.057134,"eighty":-1.258227,"marketCap":22025933},{"date":"2025-01-17","current":-1.768009,"twenty":-5.779566,"median":-2.037542,"eighty":-1.258227,"marketCap":19873022},{"date":"2025-01-24","current":-1.664875,"twenty":-5.732546,"median":-2.035768,"eighty":-1.259831,"marketCap":18713762},{"date":"2025-01-31","current":-1.856409,"twenty":-5.367769,"median":-2.010846,"eighty":-1.260232,"marketCap":20866673},{"date":"2025-02-07","current":-1.723809,"twenty":-5.033478,"median":-1.997597,"eighty":-1.260232,"marketCap":19376196},{"date":"2025-02-14","current":-1.753275,"twenty":-4.268723,"median":-1.967235,"eighty":-1.268496,"marketCap":19707413},{"date":"2025-02-21","current":-1.635408,"twenty":-4.064306,"median":-1.959359,"eighty":-1.271301,"marketCap":18382545},{"date":"2025-02-28","current":-1.502808,"twenty":-3.940055,"median":-1.950359,"eighty":-1.271793,"marketCap":16892069},{"date":"2025-03-07","current":-1.488074,"twenty":-3.869935,"median":-1.934829,"eighty":-1.271793,"marketCap":16726460},{"date":"2025-03-14","current":-1.841676,"twenty":-3.869935,"median":-1.920187,"eighty":-1.27873,"marketCap":20701065},{"date":"2025-03-21","current":-1.797476,"twenty":-3.846869,"median":-1.893243,"eighty":-1.290292,"marketCap":20204239},{"date":"2025-03-28","current":-1.620675,"twenty":-3.823803,"median":-1.885876,"eighty":-1.294917,"marketCap":18216937},{"date":"2025-04-04","current":-1.927027,"twenty":-3.8033,"median":-1.893243,"eighty":-1.309909,"marketCap":15132288},{"date":"2025-04-11","current":-1.806267,"twenty":-3.701093,"median":-1.885876,"eighty":-1.319904,"marketCap":14183998},{"date":"2025-04-17","current":-2.291021,"twenty":-3.602316,"median":-1.885876,"eighty":-1.323783,"marketCap":17990609},{"date":"2025-04-25","current":-2.128723,"twenty":-3.467739,"median":-1.885876,"eighty":-1.330657,"marketCap":16716134},{"date":"2025-05-02","current":-2.440901,"twenty":-3.248312,"median":-1.90061,"eighty":-1.333733,"marketCap":19167565},{"date":"2025-05-09","current":-2.676427,"twenty":-3.087659,"median":-1.92061,"eighty":-1.335972,"marketCap":21017067},{"date":"2025-05-16","current":-3.015077,"twenty":-3.060231,"median":-1.929591,"eighty":-1.33782,"marketCap":23875388},{"date":"2025-05-23","current":-2.611651,"twenty":-3.060231,"median":-1.942197,"eighty":-1.340821,"marketCap":20680794},{"date":"2025-05-30","current":-2.845213,"twenty":-3.032803,"median":-1.954767,"eighty":-1.341164,"marketCap":22530296},{"date":"2025-06-06","current":-2.927246,"twenty":-3.016719,"median":-1.959543,"eighty":-1.343476,"marketCap":23179883},{"date":"2025-06-13","current":-2.649478,"twenty":-3.012039,"median":-1.970481,"eighty":-1.352726,"marketCap":20980332},{"date":"2025-06-20","current":-2.628111,"twenty":-2.999889,"median":-1.99311,"eighty":-1.352726,"marketCap":20811136},{"date":"2025-06-27","current":-2.585377,"twenty":-2.991346,"median":-2.003743,"eighty":-1.36142,"marketCap":20472743},{"date":"2025-07-03","current":-2.564011,"twenty":-2.980626,"median":-2.014046,"eighty":-1.36845,"marketCap":20303547},{"date":"2025-07-11","current":-2.564011,"twenty":-2.973678,"median":-2.023876,"eighty":-1.374721,"marketCap":20303547},{"date":"2025-07-18","current":-4.711669,"twenty":-3.002927,"median":-2.037346,"eighty":-1.385099,"marketCap":37310135},{"date":"2025-07-25","current":-4.058566,"twenty":-3.076478,"median":-2.047338,"eighty":-1.397154,"marketCap":32138433},{"date":"2025-08-01","current":-3.84864,"twenty":-3.389372,"median":-2.057134,"eighty":-1.420873,"marketCap":30476100},{"date":"2025-08-08","current":-3.195538,"twenty":-3.551253,"median":-2.064723,"eighty":-1.428551,"marketCap":25304398},{"date":"2025-08-15","current":-3.428789,"twenty":-3.546261,"median":-2.076725,"eighty":-1.436037,"marketCap":27151435},{"date":"2025-08-22","current":-3.438101,"twenty":-3.551253,"median":-2.088717,"eighty":-1.466225,"marketCap":26697041},{"date":"2025-08-29","current":-3.438101,"twenty":-3.546261,"median":-2.106877,"eighty":-1.473341,"marketCap":26697041},{"date":"2025-09-05","current":-3.388985,"twenty":-3.525507,"median":-2.115909,"eighty":-1.473341,"marketCap":26315654},{"date":"2025-09-10","current":-3.462659,"twenty":-3.506863,"median":-2.132112,"eighty":-1.474654,"marketCap":26887734}],"updateTime":1757611196689},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MIRA\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2548817759","title":"BRIEF-Mira Pharmaceuticals says Mira-55 Shows Morphine-Comparable Pain Relief Without Opioid Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2548817759","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548817759?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:13","pubTimestamp":1751487185,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals says Mira-55 Shows Morphine-Comparable Pain Relief Without Opioid RisksJuly 2  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - MIRA-55 SHOWS MORPHINE-COMPARABLE PAIN RELIEF WITHOUT OPIOID RISKS - SEC FILINGFurther company coverage: MIRA.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nFWN3SZ087:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2548817473","title":"MIRA Pharmaceuticals Advances with Regulatory Green Light for Mira-55, Clearing Path for Clinical Development in Pain Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2548817473","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548817473?lang=en_us&edition=fundamental","pubTime":"2025-07-03 04:07","pubTimestamp":1751486833,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Advances with Regulatory Green Light for Mira-55, Clearing Path for Clinical Development in Pain Management. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on July 02, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250702:nNDL37hbBZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2547096336","title":"BRIEF-Mira Pharmaceuticals Announces New Study Results For SKNY-1 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2547096336","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547096336?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:38","pubTimestamp":1751283483,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Announces New Study Results For SKNY-1 - SEC FilingJune 30  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ANNOUNCES NEW STUDY RESULTS FOR SKNY-1 - SEC FILINGMIRA PHARMACEUTICALS INC - IN ANIMAL MODEL OF OBESITY & CRAVING USING SKNY-1 REDUCED BODY WEIGHT BY APPROXIMATELY 30% AFTER JUST SIX DAYSMIRA PHARMACEUTICALS INC - TREATED ANIMALS WEIGH 10% LESS THAN HEALTHY CONTROLS - SEC FILINGMIRA PHARMACEUTICALS: IN UNTREATED OBESE ANIMALS, FAT BUILDUP IN THE LIVER WAS ABOUT 50% HIGHER THAN NORMALSource text: [ID:n0001641172-25-017046]Further company coverage: MIRA.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nFWN3SX0AL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2547009501","title":"Mira Pharmaceuticals Unveils Promising Results for SKNY-1, Showing 30% Weight Loss and Reduced Cravings in Obesity Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2547009501","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547009501?lang=en_us&edition=fundamental","pubTime":"2025-06-30 19:31","pubTimestamp":1751283094,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc.  has announced new results from an animal study involving SKNY-1, an oral therapeutic under definitive agreement for acquisition from SKNY Pharmaceuticals, Inc. The study, conducted using a zebrafish model that simulates human obesity and craving behaviors, demonstrated that SKNY-1 achieved significant outcomes within six days of treatment. Notably, SKNY-1 resulted in up to 30% weight loss while preserving muscle density, increased metabolic activity, and improved liver and lipid profiles. Additionally, SKNY-1 was found to reduce nicotine cravings and compulsive behaviors, as well as normalize neurohormonal imbalances associated with obesity. These findings support the advancement of SKNY-1 toward Investigational New Drug -enabling studies, with Mira Pharmaceuticals prioritizing it as a potential cornerstone asset in light of the significant global market opportunity for obesity and smoking-related therapies.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL4ym1LX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2546217559","title":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2546217559","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546217559?lang=en_us&edition=fundamental","pubTime":"2025-06-25 20:00","pubTimestamp":1750852827,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. Awaits Regulatory Approval for Acquisition of SKNY Pharmaceuticals, Aiming to Revolutionize Weight Loss and Smoking Cessation Markets with SKNY-1. Mira Pharmaceuticals Inc.  has announced that its acquisition of SKNY Pharmaceuticals, Inc. is currently undergoing regulatory review. This acquisition involves SKNY's promising drug candidate, SKNY-1, which targets weight loss and smoking cessation without central nervous system side effects. The review process requires approval from regulatory authorities and a shareholder vote, in accordance with SEC regulations. Successful completion of this acquisition could position SKNY-1 as a cornerstone asset within Mira's pipeline, addressing major health challenges in obesity and nicotine addiction. The approval is pending and no grant or funding from multiple organizations has been specified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to pro","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250625:nNDL99FqMP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2544972759","title":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2544972759","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544972759?lang=en_us&edition=fundamental","pubTime":"2025-06-18 20:30","pubTimestamp":1750249851,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals Announces Progress in Phase 1 Trial for Lead Drug Candidate Ketamir-2, Prepares for Phase 2a Initiation by Year-End 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire  on June 18, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDLc9fVmL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2544990199","title":"Mira Pharmaceuticals Advances Ketamir-2 Development with SEC Regulatory Filings for SKNY Pharmaceuticals Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2544990199","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544990199?lang=en_us&edition=fundamental","pubTime":"2025-06-18 04:02","pubTimestamp":1750190526,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. recently announced progress in its regulatory endeavors, as the acquisition of SKNY Pharmaceuticals is advancing as planned. The company has successfully submitted the necessary regulatory filings for the merger to the U.S. Securities and Exchange Commission . This acquisition includes SKNY Pharmaceuticals' first-in-class oral CB1/CB2 inverse agonist for obesity and smoking cessation, SKNY-1. Furthermore, Mira Pharmaceuticals is on track to initiate a Phase 2a trial for Ketamir-2 in neuropathic pain by year-end 2025, pending regulatory clearance. This development marks a significant step in Mira Pharmaceuticals' clinical pipeline expansion.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9vnzb9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2544962331","title":"Mira Pharmaceuticals Inc. Announces Date for Virtual Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2544962331","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544962331?lang=en_us&edition=fundamental","pubTime":"2025-06-17 20:03","pubTimestamp":1750161802,"startTime":"0","endTime":"0","summary":"MIRA Pharmaceuticals, Inc. is set to hold a virtual special meeting of its stockholders. Details regarding the specific date of the meeting have not been disclosed in the available information. During this meeting, stockholders will vote on proposals and resolutions brought forth by the board of directors. Further specifics about the proposals to be discussed or voted on have not been provided.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2025, and is solely responsible for the information contained there","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9zLl33:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2542131621","title":"Mira Pharmaceuticals Inc. Files Initial Statement of Beneficial Ownership for CFO Alan Weichselbaum","url":"https://stock-news.laohu8.com/highlight/detail?id=2542131621","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542131621?lang=en_us&edition=fundamental","pubTime":"2025-06-10 19:13","pubTimestamp":1749554008,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has filed an initial statement of beneficial ownership. The filing identifies Alan Weichselbaum as the beneficial owner, who holds the position of Chief Financial Officer at the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2qyH4m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA","BK4007"],"gpt_icon":0},{"id":"2538473062","title":"Mira Pharmaceuticals Nears Finalization of SKNY Pharmaceuticals Acquisition with Regulatory Filings Imminent","url":"https://stock-news.laohu8.com/highlight/detail?id=2538473062","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538473062?lang=en_us&edition=fundamental","pubTime":"2025-05-28 20:01","pubTimestamp":1748433677,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced progress in its acquisition of SKNY Pharmaceuticals Inc. The company is finalizing the necessary regulatory filings and expects to submit the required documentation to the U.S. Securities and Exchange Commission in the coming weeks. SKNY's lead development candidate, SKNY-1, focuses on smoking cessation and obesity treatment, targeting CB1, CB2, and MAO-B receptors. This acquisition is part of Mira's strategy to expand its portfolio and explore therapeutic areas with significant unmet needs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syste","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250528:nNDL5Z346N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2537040952","title":"BRIEF-Mira Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2537040952","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537040952?lang=en_us&edition=fundamental","pubTime":"2025-05-22 06:42","pubTimestamp":1747867340,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Inc - Michelle Yanez Steps Down As CFO Of Mira Pharmaceuticals - SEC FilingMira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - MICHELLE YANEZ STEPS DOWN AS CFO OF MIRA PHARMACEUTICALS - SEC FILINGMIRA PHARMACEUTICALS INC - ALAN WEICHSELBAUM APPOINTED AS CFO OF MIRA PHARMACEUTICALS - SEC FILINGSource text: [ID:n0001641172-25-011936]Further company coverage: MIRA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250521:nFWN3RT3EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MIRA"],"gpt_icon":0},{"id":"2533813601","title":"BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2533813601","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533813601?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:51","pubTimestamp":1746705100,"startTime":"0","endTime":"0","summary":"BRIEF-Mira Pharmaceuticals Agrees To Acquire Skny Pharmaceuticals - SEC FilingMay 8  - Mira Pharmaceuticals Inc MIRA.O:MIRA PHARMACEUTICALS INC - ON APRIL 30, AGREED TO ACQUIRE SKNY PHARMACEUTICALS - SEC FILINGMIRA PHARMACEUTICALS INC - COMBINED ENTERPRISE VALUE EXCEEDS $60 MILLION - SEC FILINGMIRA PHARMACEUTICALS INC -UNDER DEAL SKNY TO CONTRIBUTE $5 MILLION TO MIRA AT CLOSING - SEC FILINGSource text: [ID:n0001641172-25-009155]Further company coverage: MIRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RG1J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0},{"id":"2533181211","title":"MIRA Pharmaceuticals Acquires SKNY Pharmaceuticals, Boosting Enterprise Value to Over $60 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2533181211","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533181211?lang=en_us&edition=fundamental","pubTime":"2025-05-08 19:31","pubTimestamp":1746703907,"startTime":"0","endTime":"0","summary":"Mira Pharmaceuticals Inc. has announced a definitive agreement to acquire SKNY Pharmaceuticals Inc., a biotechnology company specializing in therapies for obesity and nicotine dependence. The acquisition, unanimously approved by Mira's Board of Directors, follows independent valuations by Moore Financial Consulting, which valued SKNY at approximately $30.5 million and Mira at $30 million. As part of the transaction, SKNY will contribute $5 million in assets or cash to Mira upon closing. This strategic move is expected to bolster Mira's balance sheet and enhance its development initiatives, creating a combined enterprise with a value exceeding $60 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. publishe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nNDL1bmqqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MIRA"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":68,"code":"91000000","status":"200"}]}}